<?xml version="1.0" encoding="UTF-8" standalone="no"?><document id="DrugDDI.d272" origId="Nitazoxanide"><sentence id="DrugDDI.d272.s0" origId="s0" text="Tizoxanide is highly bound to plasma protein ( 99.9%)."><entity charOffset="0-10" id="DrugDDI.d272.s0.e0" origId="s0.p0" text="Tizoxanide" type="drug"/><entity charOffset="30-44" id="DrugDDI.d272.s0.e1" origId="s0.p4" text="plasma protein" type="drug"/><pair e1="DrugDDI.d272.s0.e0" e2="DrugDDI.d272.s0.e1" id="DrugDDI.d272.s0.p0" interaction="true"/></sentence><sentence id="DrugDDI.d272.s1" origId="s1" text="Therefore, caution should be used when administering nitazoxanide concurrently with other highly plasma protein-bound drugs with narrow therapeutic indices, as competition for binding sites may occur (e.g., warfarin)."><entity charOffset="53-65" id="DrugDDI.d272.s1.e0" origId="s1.p14" text="nitazoxanide" type="drug"/><entity charOffset="207-215" id="DrugDDI.d272.s1.e1" origId="s1.p24" text="warfarin" type="drug"/><pair e1="DrugDDI.d272.s1.e0" e2="DrugDDI.d272.s1.e1" id="DrugDDI.d272.s1.p0" interaction="true"/></sentence><sentence id="DrugDDI.d272.s2" origId="s2" text="In vitro metabolism studies have demonstrated that tizoxanide has no significant inhibitory effect on cytochrome P450 enzymes."><entity charOffset="51-61" id="DrugDDI.d272.s2.e0" origId="s2.p29" text="tizoxanide" type="drug"/><entity charOffset="102-117" id="DrugDDI.d272.s2.e1" origId="s2.p32" text="cytochrome P450" type="drug"/><pair e1="DrugDDI.d272.s2.e0" e2="DrugDDI.d272.s2.e1" id="DrugDDI.d272.s2.p0" interaction="false"/><negationtags>In vitro metabolism studies have demonstrated that tizoxanide has &lt;xcope&gt;&lt;cue&gt;no&lt;/cue&gt; significant inhibitory effect on cytochrome P450 enzymes&lt;/xcope&gt;.</negationtags></sentence><sentence id="DrugDDI.d272.s3" origId="s3" text="Although no drug-drug interaction studies have been conducted in vivo, it is expected that no significant interaction would occur when nitazoxanide is co-administered with drugs that either are metabolized by or inhibit cytochrome P450 enzymes."><entity charOffset="135-147" id="DrugDDI.d272.s3.e0" origId="s3.p46" text="nitazoxanide" type="drug"/><entity charOffset="172-177" id="DrugDDI.d272.s3.e1" origId="s3.p49" text="drugs" type="drug"/><entity charOffset="220-235" id="DrugDDI.d272.s3.e2" origId="s3.p57" text="cytochrome P450" type="drug"/><pair e1="DrugDDI.d272.s3.e0" e2="DrugDDI.d272.s3.e1" id="DrugDDI.d272.s3.p0" interaction="false"/><pair e1="DrugDDI.d272.s3.e0" e2="DrugDDI.d272.s3.e2" id="DrugDDI.d272.s3.p1" interaction="false"/><pair e1="DrugDDI.d272.s3.e1" e2="DrugDDI.d272.s3.e2" id="DrugDDI.d272.s3.p2" interaction="false"/><negationtags>Although &lt;xcope&gt;&lt;cue&gt;no&lt;/cue&gt; drug-drug interaction studies have been conducted in vivo&lt;/xcope&gt;, it is expected that &lt;xcope&gt;&lt;cue&gt;no&lt;/cue&gt; significant interaction would occur when nitazoxanide is co-administered with drugs that either are metabolized by or inhibit cytochrome P450 enzymes&lt;/xcope&gt;.</negationtags></sentence></document>